Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefapixant in Women with Chronic Cough and Stress Urinary Incontinence
2019-002321-29Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic cough and stress urinary incontinence (SUI) comparing Gefapixant with Placebo (2 arms). Primary endpoint: Percent change from baseline in average daily cough-induced stress urinary incontinence episodes at Week 12. Started Oct 2019; status: completed.
02
Drugs
gefapixant
03
Conditions
chronic coughstress urinary incontinence (SUI)
Beyond the preview
Go deeper on 2019-002321-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002321-29.